Why Myriad Genetics Surged on Its Prenatal Sale—and What Still Needs Fixing

Executive Summary

Myriad Genetics shares rallied about 36% intraday on October 20 after the company announced an agreement to sell its prenatal testing business to Labcorp. Separate reports captured a similarly sized move at different times; this is an approximate intraday reaction, not a closing return. Investing.com, Benzinga

The consideration is $210 million in cash plus inventory value at closing. The agreement covers the Prequel, Foresight, SneakPeek and FirstGene testing businesses. Completion is expected by early 2027, subject to regulatory clearance and customary conditions. Transaction announcement, RTTNews

Our assessment: the agreement offers a credible improvement in financial flexibility. A sustained recovery also requires better performance from the operations Myriad retains.

Why This Matters

Myriad entered this announcement after a difficult operating period. Its July outlook reduced annual revenue guidance to $770–$790 million from $860–$880 million, and management suspended adjusted EBITDA guidance. That history makes a signed asset sale consequential: it advances a restructuring previously dependent on management’s plans. PRISM MarketView, Benzinga

The Thesis

Management expects the disposal to improve growth and profitability while supporting investment in cancer care. That is an expectation to test against subsequent results. The distinction matters because the latest quarterly filing shows reimbursement weakness within the cancer business itself. Company announcement, Quarterly filing